Efavirenz's complications.
D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use*; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D010078:Oxazines / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D019438:Ritonavir / Q000009:adverse effects*; D019258:Saquinavir / Q000009:adverse effects*; D014481:United States
D019380:Anti-HIV Agents; D015507:Drugs, Investigational; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D019258:Saquinavir; D019438:Ritonavir